MAIN

Session 7: Histopathological reclassification in WHO 2026 as a navigator of clinical trials

Session 6: Oligometastatic or oligoprogressive disease

Session 5: Imaging and pathologic response of soft tissue sarcomas to neo-adjuvant therapy

Debate I - (Neo)adjuvant or not

BREAK

Session 4: Radiotherapy updates in sarcomas: Know how session

Session 3: Rhabdomyosarcoma

BREAK

Session 2: Molecular analysis in Sarcomas: Why, how, when, what

Session 1: Artificial intelligence in sarcoma